Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-108 plus sintilimab in advanced or metastatic non-small cell lung cancer
ChiCTR2300077073Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of LM-108 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: objective response rate. Started Oct 2023; status: recruiting.
02
Drugs
LM-108
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300077073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077073.